Navigation Links
Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market
Date:7/31/2014

New York, New York (PRWEB) July 31, 2014

The controversy surrounding uterine morcellation continues to grow, as Bernstein Liebhard LLP notes that Johnson & Johnson’s Ethicon, Inc. unit has announced that it plans to voluntarily remove its power morcellators (http://www.gynecaremorcellatorlawsuit.com/) from the market. According to a report from Bloomberg.com, the company said it decided to do so because the risks and benefits associated with the devices remain uncertain.*

“In light of mounting evidence linking uterine morcellation to the spread of undetected cancers, it’s not surprising that Johnson & Johnson’s Ethicon unit has decided to pull its power morcellators from the market,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now evaluating morcellator lawsuits on behalf of women who may have experienced the spread of undiagnosed cancers due to uterine morcellation.

Morcellation and Uterine Cancer
Power morcellators are used to cut up tissue during laparoscopic hysterectomy and fibroid removal so that it can be removed through a small abdominal incision. According to Bloomberg.com, Johnson & Johnson and Ethicon decided to suspend sales of the power morcellators on April 30, 2014, after the U.S. Food & Drug Administration (FDA) warned that use of the devices in gynecological procedures could spread undetected uterine cancer cells throughout a woman’s body, resulting in an upstaging of the disease and greatly reducing her chances of long-term survival.

Since the FDA issued its alert, the controversy surrounding uterine morcellation has only grown. Earlier this month, the agency convened a panel of outside advisors to discuss the matter. According to a report from The Boston Globe, the panelists heard emotional testimony from cancer victims and their families, many of whom urged the FDA to ban power morcellators.**

On July 22nd, the Journal of the American Medical Association published a study that suggested the concerns surrounding uterine morcellation are well-founded. Among other things, the study found that as many as 1 in 368 women undergoing such procedures may have undiagnosed cancers present in their uterus. While women over 65 were more likely to have undetected cancer, the study found that 32 percent of the morcellation patients with undiagnosed disease were younger than 50.**

Women who allegedly experienced the spread of uterine cancers due to a power morcellator may be entitled to compensation from the manufacturer of the device used in their surgery. To learn more about the process for filing a morcellator lawsuit, please visit Bernstein Liebhard LLP’s website. To obtain a free legal review, please call 800-511-5092.

*bloomberg.com/news/2014-07-31/j-j-withdraws-hysterectomy-device-tied-to-cancer-spread.html, Bloomberg.com, July 31, 2014
**bostonglobe.com/lifestyle/health-wellness/2014/07/11/agreement-reached-whether-fda-should-ban-hysterectomy-cutting-tool/EkXZaFAUUnT5HZ7DBQvWbM/story.html, Boston Globe, July 11, 2014
***jama.jamanetwork.com/article.aspx?articleid=1890400, JAMA, July 22, 2014

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.gynecaremorcellatorlawsuit.com/
https://plus.google.com/115936073311125306742?rel=author

Read the full story at http://www.prweb.com/releases/morcellator-lawsuit/morcellator-cancer/prweb12062778.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Have You Had a Hysterectomy or Removal of Uterine Fibroids? Morcellator Device Withdrawn From Market Due To Cancer Risk
2. Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation
3. Amanda Leto’s Fibroids Miracle Review Reveals Clinically Proven Uterine Fibroids Cure System
4. World’s Largest Uterine Fibroid Removed from Patient
5. Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk
6. Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer
7. Study examines presence of uterine cancers at the time of hysterectomy using morcellation
8. FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids
9. Journal Maturitas publishes position statement on management of uterine fibroids
10. Bariatric surgery decreases risk of uterine cancer
11. DrugRisk Alerts of New Rise In Mirena Lawsuits Alleging Uterine Damage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Compensation Research Institute (WCRI) officially opened registration today for its 33rd Annual ... in Boston, MA . , The theme of the conference is “Persistent Challenges ...
(Date:12/8/2016)... and JENNERSVILLE, Pa. (PRWEB) , ... December 08, ... ... that Penn Medicine Southern Chester County, a Property owned by an affiliate of ... million, 72,000 square foot Penn Medicine Southern Chester County ambulatory care center (ACC) ...
(Date:12/8/2016)... ... ... With the increasing demand for dental implants, the National Association of Dental Laboratories ... and patients about the safety issues related to dental restorations. According to the American ... projected to reach $6.4 billion in 2018 with more than 30 million Americans missing ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView Software ... and employees that are both engaging and easy to use. Coming off the ... software company revealed today its plans to roll out new AI-powered self-service enhancements ...
(Date:12/8/2016)... ... December 08, 2016 , ... STATEN ISLAND, N.Y., ... for adherence to the highest standards of trauma, maternity, cancer and chronic obstructive ... president and CEO, Dr. Daniel Messina. , Among the recognitions, the American College ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Australia Glaucoma Surgery Devices Market Outlook ... "Australia Glaucoma Surgery Devices Market Outlook to 2022", ... Surgery Devices market. The report provides value, in ... average prices (USD) within market segement - Glaucoma ... shares and distribution shares data for each of ...
(Date:12/8/2016)... KEY FINDINGS The global medical lifting sling ... for growth of the medical lifting sling market are ... high recovery cost of injuries and government initiatives to ... refers to an assistive device that helps caregiver transfer ... the lift and hold the patient. It is important ...
(Date:12/8/2016)... 8, 2016  Eli Lilly and Company (NYSE: ... phase 3 EXPEDITION3 trial at the 9 th ... disclosed, solanezumab did not meet the primary endpoint in ... in people with mild dementia due to Alzheimer,s disease ... solanezumab for the treatment of mild dementia due to ...
Breaking Medicine Technology: